Phase 2Completed
Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain
A Phase IIb, Randomized, Open-labeled Trial to Evaluate the Immunogenicity and Safety of One or Two Doses of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain in Adults in Hong Kong
- Sponsor
- Sinovac Biotech (Hong Kong) Limited (Industry)
- Enrolment
- 221 enrolled
- Conditions
- COVID-19
- Interventions
- COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain
- Ages
- adults, older adults
- Registry
- NCT05411471
Full record on ClinicalTrials.gov
From the registry
This is a randomized, open-labeled, Phase IIb clinical trial.The purpose of this study is to evaluate the immunogenicity and safety of the booster vaccine of using one or two doses of COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain in Adults above 18 Years Old Who Have Completed Two or Three Doses of mRNA Vaccine or CoronaVac®.
Primary outcomes
- Geometric mean of neutralization antibody titre (GMT)
- Occurrence, intensity, duration, and relationship of solicited local and systemic AEs
History
Last registry update
Primary completion
Registered
Started